Company Overview

CommBio Therapeutics is dedicated to developing a new class of medicine – genetically engineered bacteria, for a broad range of complex diseases. This novel modality, termed bacterial vector gene therapy or recombinant live biotherapeutics, leverages the rapid advances in the field of intestine biology and powered by the development of synthetic biology tools over the last two decades.

Scientific research continues to provide evidence that many diseases’ are modulated by signals/targets from within the gut. Our approach at CommBio is to integrate disease-curing-genes into the chromosome of gut bacteria using synthetic biology tools, such that these bacteria can accurately deliver disease modulating signals as they pass through the human gut. We believe that this modality has great potential to become a breakthrough therapy for specific types of diseases. As of now, programs in our pipeline target a broad range of indications including metabolic, autoimmune, neurodegenerative diseases, and cancer. Along-side our drug pipeline, we have also designed bacteria based products that address daily health needs such as alcohol metabolism that prevent hangovers as well as associated toxicities, and products that assist weight loss, which we plan to develop as consumer products.

CommBio was founded in Zhangjiang Pharma Valley, Shanghai, China in 2019 by two experienced scientists from The Novartis Institutes for BioMedical Research (NIBR). Our current team include pharmaceutical industry veterans, world-renowned scientists, and experts in IP, finance and operations. 80% of our FTE work in R&D function. About third of our employees hold PhD degree, and about fourth have studied or worked abroad (returnees).

  • Our Vision

    Our Vision

    To pioneer and become the leading company in the application of bacterial vector gene therapy to meet the medical needs of patients in the Chinese and global markets.

  • Our Mission

    Our Mission

    To bring high quality, first-in-class and best-in-class therapeutics to patients in China and worldwide that are safe, effective and affordable by a restless and relentless dedication to innovation.

  • Our Values

    Our Values

    Science, Innovation, Dedication

CommBio was founded in Zhangjiang Pharma Valley, Shanghai, China in 2019 by two experienced scientists from The Novartis Institutes for BioMedical Research (NIBR). Our current team include pharmaceutical industry veterans, world-renowned scientists and experts in IP, finance and operations.

Bin Xiang, PhD

Bin Xiang, PhD

Co-Founder & Chief Executive Officer

Dachen Cheng, PhD

Dachen Cheng, PhD

Co-Founder & Chief Operations Officer

Peter Atadja, PhD

Peter Atadja, PhD

Chief Scientific Officer

Gregory Fanning, PhD

Gregory Fanning, PhD

Chief Business Officer

Meixi Chen

Meixi Chen

Executive Vice President

Li Zhu, PhD

Li Zhu, PhD

Vice President

Wei Gao, PhD

Wei Gao, PhD

Executive Director

CommBio was founded in Zhangjiang Pharma Valley, Shanghai, China in 2019 by two experienced scientists from The Novartis Institutes for BioMedical Research (NIBR). Our current team include pharmaceutical industry veterans, world-renowned scientists and experts in IP, finance and operations.

En Li, PhD

En Li, PhD

Scientific Advisory Board, Chair

Gang Pei, PhD

Gang Pei, PhD

Scientific Advisor

Jufeng Wang, PhD

Jufeng Wang, PhD

Scientific Advisor

Wei Tian, PhD

Wei Tian, PhD

Scientific Advisor

CommBio Therapeutics Co., Ltd 沪ICP备2021004953号-1

×